
We’re excited to announce that we will be presenting data from two Phase 1 studies of ATX-304 at @ObesityWeek 2026, The Obesity Society’s 44th Annual Meeting. ATX-304 is the first AMPK Network Activator to enter clinical development. Building on clinical results first presented at ADA earlier this year, our poster will show the dose- and time-dependent effects of ATX-304 on lipids, adipose tissue, and energy expenditure. • Poster-111, Exhibit Hall BCD • Saturday, November 14, 7:30–8:30 PM ET • Session: Translational Research & Emerging Metabolic Therapies Read the full release: cambrianbio.com/news-and-pub…












